secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2022-12-27T23:59:59+00:00
Accession:  0001157523-22-001788
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra amends loan with Hercules: extends interest-only period, maturity, and $20M tranche; cash runway to H2 2024
--------------------------------------------------------------------------------

- Interest-only period extended to May 1, 2024; term loan maturity extended to Oct 1, 2024.
- $20M fourth tranche commitment availability extended to May 1, 2024; subject to lender approval.
- Prepayment charge set to 0.75% of amount prepaid in first 12 months, 0% thereafter.
- Additional end-of-term charge of $292,500 added; existing $1,042,500 charge remains due Oct 1, 2023.
- Existing cash, equivalents, and marketable securities now expected to fund operations into H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001788/0001157523-22-001788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752322001788/a53133738.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer